Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14720 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von M Cobo Marcos und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Hypertonic saline solution (HSS) plus intravenous (IV) loop diuretic appears to enhance the diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this therapy in the ambulatory setting have not been evaluated. We aimed to describe the design and baseline characteristics of the SALT-HF trial participants. Methods and results ‘Efficacy of Saline Hypertonic Therapy in Ambulatory Patients with HF’ (SALT-HF) trial was a multicenter, double-blinded, and randomized study involving ambulatory patients who experienced worsening heart failure (WHF) without criteria for hospitalization. Enrolled patients had to present at least two signs of volume overload, use ≥ 80 mg of oral furosemide daily, and have elevated natriuretic peptides. Patients were randomized 1:1 to treatment with a 1-h infusion of IV furosemide plus HSS (2.6–3.4% NaCl depending on plasmatic sodium levels) versus a 1-h infusion of IV furosemide at the same dose (125–250 mg, depending on basal loop diuretic dose). Clinical, laboratory, and imaging parameters were collected at baseline and after 7 days, and a telephone visit was planned after 30 days. The primary endpoint was 3-h diuresis after treatment started. Secondary endpoints included (a) 7-day changes in congestion data, (b) 7-day changes in kidney function and electrolytes, (c) 30-day clinical events (need of IV diuretic, HF hospitalization, cardiovascular mortality, all-cause mortality or HF-hospitalization).
Results
A total of 167 participants [median age, 81 years; interquartile range (IQR), 73–87, 30.5% females] were randomized across 13 sites between December 2020 and March 2023. Half of the participants (n = 82) had an ejection fraction >50%. Most patients showed a high burden of comorbidities, with a median Charlson index of 3 (IQR: 2–4). Common co-morbidities included diabetes mellitus (41%, n = 69), atrial fibrillation (80%, n = 134), and chronic kidney disease (64%, n = 107). Patients exhibited a poor functional NYHA class (69% presenting NYHA III) and several signs of congestion. The mean composite congestion score was 4.3 (standard deviation: 1.7). Ninety per cent of the patients (n = 151) presented oedema and jugular engorgement, and 71% (n = 118) showed lung B lines assessed by ultrasound. Median inferior vena cava diameter was 23 mm, (IQR: 21–25), and plasmatic levels of N-terminal-pro-B-type natriuretic peptide (NTproBNP) and antigen carbohydrate 125 (CA125) were increased (median NT-proBNP 4969 pg/mL, IQR: 2508–9328; median CA125 46 U/L, IQR: 20–114).
Conclusions
SALT-HF trial randomized 167 ambulatory patients with WHF and will determine whether an infusion of hypertonic saline therapy plus furosemide increases diuresis and improves decongestion compared to equivalent furosemide administration alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
- Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
- Department of Cardiology, Hospital Universitario de Bellvitge, IDIBELL, Barcelona, Spain.
- Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), University of Valencia, Valencia, Spain.
- Department of Internal Medicine, Hospital Universitario Lozano Blesa, University of Zaragoza, Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
- Department of Internal Medicine, Hospital Universitario Arnau de Vilanova, Lleida, Spain.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Cobo Marcos, M., Comín-Colet, J., de la Espriella, R., Rubio Gracia, J., Morales-Rull, J. L., Zegrí, I., Llacer, P., Diez-Villanueva, P., Jiménez-Marrero, S., de Juan Bagudá, J., Ortiz Cortés, C., Goirigolzarri-Artaza, J., García-Pinilla, J. M., Barrios, E., Del Prado Díaz, S., Montero Hernández, E., Sanchez-Marteles, M., & Nuñez, J. (2024). Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.14720
Vancouver
Cobo Marcos M, Comín-Colet J, de la Espriella R, Rubio Gracia J, Morales-Rull JL, Zegrí I, et al. Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure. ESC Heart Failure. 2024. doi:10.1002/ehf2.14720
BibTeX
@article{CoboMarcos2024,
author = {Cobo Marcos, M and Comín-Colet, J and de la Espriella, R and Rubio Gracia, J and Morales-Rull, J L and Zegrí, I and Llacer, P and Diez-Villanueva, P and Jiménez-Marrero, S and de Juan Bagudá, J and Ortiz Cortés, C and Goirigolzarri-Artaza, J and García-Pinilla, J M and Barrios, E and Del Prado Díaz, S and Montero Hernández, E and Sanchez-Marteles, M and Nuñez, J},
title = {Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14720}
}
EUVIMED